Why Take-Two’s Stock Is Trading Lower Today
Take-Two Interactive Software Inc (NASDAQ: TTWO) is trading lower Tuesday morning after the company issued guidance below estimates.
Bausch Health Misses On Q2 Sales, Cuts FY21 Outlook, Plans IPO For Medical Aesthetics Business
Bausch Health Companies Inc (NYSE:BHC) has reported Q2 revenues of $2.1 billion, +26% Y/Y, and missing the consensus of $2.12…
Nikola Highlights H2’21 Milestones, Including Delivery Of Pre-Series Nikola Tre BEVs For Use On Public Roads, Added Fleet Testing Customers/Dealers
Nikola looks forward to achieving the following milestones in the second half of 2021:
Deliver pre-series Nikola Tre BEVs for use on public roads hauling customer freight;
Announce additional fleet testing
Eaton Stock Gains After Q2 Earnings Beat, Raised FY21 Adjusted EPS Outlook
Eaton Corporation PLC (NYSE:ETN) reported second-quarter sales growth of 35.4% year-over-year to $5.22 billion, beating the consensus of $4.91 billion. Sales…
The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly’s Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 2)
Under Armour Shares Jump In Premarket On Strong Q2 Earnings, Raised FY21 Guidance
Under Armour Inc (NYSE:UAA) reported second-quarter FY21 sales growth of 91% year-on-year, to $1.35 billion, beating the analyst consensus of $1.21…
Avanos Narrows FY21 Adj. EPS Guidance From $1.10-$1.25 To $1.10-$1.20 vs $1.21 Est.
Full Year 2021 Outlook
The company maintains its outlook for net sales to increase 2 to 4 percent, on a constant currency basis, compared to 2020. The company is revising its previously announced
Ingredion Q2 Earnings Crushes Estimates; Provides FY21 Guidance
Ingredion Inc (NYSE:INGR) reported second-quarter FY21 sales growth of 30.6% year-on-year, to $1.76 billion, beating the analyst consensus of $1.70 billion.…
Bausch Health Companies Q2 GAAP Net Loss $595M, Adj. EBITDA $826M, Sales $2.10B Miss $2.12B Estimate; Cuts Guidance
Bausch Health Companies (NYSE:BHC) reported quarterly sales of $2.10 billion which missed the analyst consensus estimate of $2.12 billion by 0.94 percent. This is a 26.20 percent increase over sales of $1.66 billion the
AMETEK Sees Q3 Adj. EPS $1.16-$1.18 vs $1.17 Est., Raises FY21 Adj. EPS Guidance From $4.48-$4.56 To $4.62-$4.68 vs $4.56 Est.
2021 Outlook
"We are pleased with AMETEK's performance through the first half of the year. Sales and orders growth has been broad based as the global economy continues its recovery. Our businesses are